Modality
Nanobody
MOA
CD47i
Target
Menin
Pathway
Proteasome
MGPBC
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Nov 2031
Phase 2Current
NCT04758921
934 pts·MG
2020-11→TBD·Not yet recruiting
NCT08298554
1,006 pts·MG
2018-07→2031-11·Not yet recruiting
1,940 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-265.7y awayPh2 Data· MG
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Not yet…
P2
Not yet…
Catalysts
Ph2 Data
2031-11-26 · 5.7y away
MG
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04758921 | Phase 2 | MG | Not yet recr... | 934 | UPCR |
| NCT08298554 | Phase 2 | MG | Not yet recr... | 1006 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| BGN-3859 | BeiGene | Approved | PSMA |